Latest News

Approval is based on 36-week data from BRAVE-AA-PEDS, in which 42% of patients on the 4 mg dose achieved a SALT score of 20 or less, compared with 5% on placebo.

The FDA approved once-daily oral zilurgisertib for FOP in patients aged 12 years and older after the phase 2 PROGRESS trial showed reduced new heterotopic ossification vs placebo.

Approval covers patients aged ≥2 years with frequently relapsing or steroid dependent disease in complete remission.

As the FDA weighs its first psychedelic approval, Sarah Norman, MPP, says training, credentialing, and reimbursement are lagging while patients are already asking.

Pranav Garimella discusses what a potential USPSTF kidney screening recommendation could mean for high-risk adults and primary care.

Andrea Murina, MD, weighs whether she would recommend medicine to her own children amid AI, physician burnout, and evolving residency training standards.

Two monoclonal antibodies isolated from malaria-exposed donors blocked patient IgE from binding key alpha-gal allergens and suppressed basophil activation.

Manju Dawkins, MD, discusses Skin Angels, why clinicians belong in dermatology innovation, and her work to reduce injection pain and needle anxiety.

As the USPSTF considers evidence for updated CKD screening guidance, Garimella discusses gaps in kidney disease detection and what the review should capture.

FDA clears Eli Lilly’s Onswik weekly insulin from QWINT trials, cutting injections for type 2 diabetes while matching daily basal control.

Iliyan D. Iliev, PhD, discusses how fluconazole targets gut Candida to improve disease activity in IBD.

Two 12-week phase 3 trials and a 43-week extension will test 8 mg and 16 mg HLP003 added to antidepressants, with APPROACH enrollment now complete.

This preview of EADV 2026 provides a teaser of new data and interviews being highlighted at this Vienna dermatology conference.

Phase 2b AMPLIFIED data show a 42.7% UACR drop in AMKD with modest proteinuria; AMPLITUDE interim data are due early 2027.

Agusti, chair of the GOLD Board of Directors, discusses which COPD diagnostic bottleneck AI is closest to solving and more.

George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.

Andrew Cutler, MD, says real-world MDD patients respond to adjunctive cariprazine like trial participants, with gains in mood and function within weeks.

Frances Lee, MD, on the stigma driving under-detection of ALD and its disproportionate rise in women and younger adults.

SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.

EMBARQ-CSU1 and EMBARQ-CSU2 showed sustained reductions in urticaria, with the antibody meeting all primary and key secondary endpoints at Week 12.

The FDA-approved update adds phase 3 HYPERION data on adults diagnosed with PAH within the past year.

Josh Woolley, MD, PhD, explains why current active placebos fail to mask high-dose psilocybin trials and outlines a framework proposed to fix it.

Raj Chovatiya, MD, PhD, on zasocitinib results in the scalp, nails, palms and soles, speed of response and once-daily oral dosing in psoriasis.